Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from TGTX

Biotech Stock TG Therapeutics Hits A High In Market Meltdown

Biotech stock TG Therapeutics is outperforming the major indexes in a declining stock market. TGTX stock hit a new high on Friday.

Investors Business Daily

S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout

S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout

These watch list stocks have beenholding near buy points while the market has been breaking down.

Investors Business Daily

This Biotech Stock Hits Buy Point After Earnings Burst

This Biotech Stock Hits Buy Point After Earnings Burst

TGTX stock is climbing and broke out of a base Thursday. TG Therapeutics reported a robust earnings report on Monday.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?

TG Therapeutics shares soared Wednesday after sales of its multiple sclerosis treatment met expectations. TGTX stock topped its 200-day line.

Investors Business Daily

3 Biotech Stocks Investors Are Watching for Future Growth

A wide range of applications across several sectors, supportive government initiatives, rapid technological advancements, and shifting market dynamics position the biotechnology industry for robust long-term growth. Given the industry’s bright outlook, biotech stocks MannKind (MNKD), Illumina (ILMN), and TG Therapeutics (TGTX) could be ideal watchlist additions for potential growth. Read…

TG Therapeutics Reverses Its 225% Winning Streak On Lackluster Guidance

Sales of a new multiple sclerosis drug from TG crushed analysts' expectations, but TGTX stock tumbled on lackluster 2024 guidance.

Investors Business Daily

Are These 4 Biotech Stocks Worth Buying in 2024?

The need for innovative healthcare solutions, personalized medicines and treatments, and the use of advanced technologies will propel the biotech industry forward. Amid this backdrop, let’s explore the investment potential of biotech stocks TG Therapeutics (TGTX), Galapagos (GLPG), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR).

inkl

Read news from The Economist, FT, and more,
with one subscription

Sales Of TG Therapeutics' New Product Doubled — Here's Why Shares Halved

Sales Of TG Therapeutics' New Product Doubled — Here's Why Shares Halved

Sales of TG Therapeutics' highly anticipated multiple sclerosis drug, Briumvi, missed forecasts on Tuesday and TGTX stock plummeted.

Investors Business Daily

How Roche Just Cut Top 1% Biotech Stock TG Therapeutics Down A Peg

How Roche Just Cut Top 1% Biotech Stock TG Therapeutics Down A Peg

Roche unveiled positive results Thursday for a rival to TG Therapeutics' infusion for multiple sclerosis patients, and TGTX stock crashed.

Investors Business Daily

Top 1% Biotech TG Therapeutics Obliterates Bullish Sales Calls — And Rockets

Top 1% Biotech TG Therapeutics Obliterates Bullish Sales Calls — And Rockets

TG Therapeutics more than doubled Wall Street's first-quarter sales expectations on Monday, and TGTX stock rocketed to a five-month high.

Investors Business Daily

Top-Notch Biotech TG Therapeutics Breaks Out On 'Solid Jump' In Sales

Top-Notch Biotech TG Therapeutics Breaks Out On 'Solid Jump' In Sales

TG Therapeutics' new MS drug, Briumvi, experienced a "solid jump" in March sales, according to a report. TGTX stock broke out Tuesday.

Investors Business Daily

Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment

Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment

Growth stock TG Therapeutics has surged 80% after FDA approval for its multiple sclerosis treatment.

Investors Business Daily

Despite Price Cut, HC Wainwright Keeps Buy Rating On TG Therapeutics - Read Why

Despite Price Cut, HC Wainwright Keeps Buy Rating On TG Therapeutics - Read Why

TG Therapeutics Inc's (NASDAQ:TGTX) shares are plunging after new data showed that ublituximab /Ukoniq showed an elevated risk of death in the phase 3 Unity combo trial for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) HC Wainwright has slashed the price target from $68 to $19, with the Buy rating unchanged.…

FDA Pushes TG Therapeutics' Ublituximab / Ukoniq Combo Therapy Applications In Blood Cancer Settings

FDA Pushes TG Therapeutics' Ublituximab / Ukoniq Combo Therapy Applications In Blood Cancer Settings

The FDA has extended the review period of TG Therapeutics Inc's (NASDAQ:TGTX) biologics license application and supplemental New Drug Application for ublituximab in combination with Ukoniq (umbralisib) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The Prescription Drug User Fee Act (PDUFA) goal date is postponed to June 25. The FDA notified…

Get all your
news in one place.

100’s of premium titles.
One news app.

TG Therapeutics Falls 30% As CEO Discloses Partial Clinical Hold On Blood Cancer Trials

TG Therapeutics Inc's (NASDAQ: TGTX) CEO Michael Weiss said that the FDA has

Where TG Therapeutics Stands With Analysts

Within the last quarter, TG Therapeutics (NASDAQ:TGTX) has observed the following analyst ratings:

People

102,585 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Berkshire Hathaway

Investor Business Daily

IBD Stock Checkup

TG Therapeutics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Multiple Sclerosis

Places

255,835 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play